This website will offer limited functionality in this browser. We only support the recent versions of major browsers like Chrome, Firefox, Safari, and Edge.
CRA’s Lev Gerlovin and co-authors Walter Colasante and Pascale Diesel published a series of three articles in Cell & Gene on emerging gene and cell therapies and their impact on the market.
Read the full series below:
GLP-1 agonists were originally approved to treat Type 2 Diabetes (T2D) – but their most recent incarnations, which consist of both next generation GLP-1s and...
Achieving price solutions for combination regimens that are mutually acceptable to both industry and payers in global healthcare systems, is a challenge that...
CRA is a proud sponsor of the event covering market access, pricing, reimbursement, rare diseases, health technology assessments, health economics and outcomes...
CRA is a proud sponsor of the event. Kaitlyn Austin presents the session titled “Securing Insight Alignment to Drive Future-Proofed Strategies and...
